What does Oryzon Genomics, S.A.’s Mexican patent cover?

The allowed claims cover the use of iadademstat in combination with PD-1 or PD-L1 inhibitors to treat cancer, including small cell lung cancer (SCLC).

How long is Oryzon Genomics, S.A.’s Mexican patent expected to provide protection?

Following formal grant, the patent is expected to provide protection until at least 2040, not including any potential patent term extensions.

In which countries has Oryzon Genomics, S.A. secured patent protection for these iadademstat combinations?

Oryzon Genomics, S.A. said it has secured patent protection for these combinations in Australia, Europe, Japan, Mexico and Russia.

What is the status of Oryzon Genomics, S.A.’s corresponding patent applications in other jurisdictions?

Corresponding patent applications from Oryzon Genomics, S.A. remain under examination in other jurisdictions.

How does Oryzon Genomics, S.A. explain the importance of the Mexican patent decision?

Neus Virgili, Oryzon Genomics, S.A.’s Chief IP Officer, said the decision further strengthens global intellectual property protection around iadademstat and its use in combination therapies.

Which immune checkpoint inhibitors is Oryzon Genomics, S.A. exploring with iadademstat?

Oryzon Genomics, S.A. said it is exploring iadademstat with immune checkpoint inhibitors such as atezolizumab and durvalumab in small cell lung cancer.

What clinical trials are investigating Oryzon Genomics, S.A.’s iadademstat combinations?

Iadademstat is being investigated with PD-L1 inhibitors in two ongoing clinical trials in extensive-stage small cell lung cancer (ES-SCLC). One is a Phase I/II study of iadademstat with atezolizumab or durvalumab, while the other is an open-label Phase Ib study of iadademstat with atezolizumab and stereotactic body radiation therapy (SBRT), followed by maintenance therapy with atezolizumab and iadademstat.

Who is conducting Oryzon Genomics, S.A.’s Phase I/II iadademstat combination study?

The Phase I/II study is conducted and sponsored by the U.S. National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Oryzon Genomics, S.A., and is being carried out at more than 30 clinical sites across the United States.

Who sponsors Oryzon Genomics, S.A.’s Phase Ib iadademstat study and what does it evaluate?

Yale University sponsors and conducts the open-label Phase Ib study. It evaluates iadademstat with atezolizumab and SBRT, followed by maintenance therapy with atezolizumab and iadademstat in patients with residual, progressive or recurrent ES-SCLC.

What does Oryzon Genomics, S.A. do?

Oryzon Genomics, S.A. describes itself as a clinical-stage biopharmaceutical company and global leader in epigenetics.

What are Oryzon Genomics, S.A.’s ISIN code and ticker symbol?

Oryzon Genomics, S.A. is identified in the announcement by ISIN Code ES0167733015 and the ticker symbol ORY.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon reports Mexican decision to grant patent for iadademstat combinations

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon reports Mexican decision to grant patent for iadademstat combinations

Published Thursday, 12 March 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Regulatory approval
Published: Thursday, 12 March 2026
Source announcement: oryzon.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced a Mexican patent decision covering iadademstat combinations.

The Mexican Patent Office decided to grant patent application MX/a/2021/011610, “Combinations of iadademstat for cancer therapy.”
Allowed claims cover iadademstat with PD-1 or PD-L1 inhibitors for cancer, including SCLC.
Following formal grant, protection is expected until at least 2040, excluding potential patent term extensions.

Protection is secured in Australia, Europe, Japan, Mexico and Russia; other applications remain under examination.

Investor FAQs

Oryzon Genomics, S.A. announced that the Mexican Patent Office had issued a decision to grant its patent application MX/a/2021/011610, entitled “Combinations of iadademstat for cancer therapy”.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors
Published: Thursday, 12 March 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…